A phase II trial of anti-EGFR ILs-dox in glioblastoma (NCT03603379) concluded that the therapy was safe but that NPs could not cross the intact blood–brain barrier to treat central nervous system tumors [161]. This evidence concerns the gene EGFR and glioblastoma.